Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: bruker.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2024 | $75.00 | Overweight | Barclays |
| 9/30/2024 | Outperform → Peer Perform | Wolfe Research | |
| 8/28/2024 | $78.00 | Overweight | Wells Fargo |
| 6/3/2024 | $85.00 | Buy | Jefferies |
| 2/14/2024 | $60.00 → $90.00 | Neutral → Overweight | JP Morgan |
| 12/19/2023 | $72.00 | Equal Weight | Wells Fargo |
| 12/13/2023 | $80.00 | Outperform | Wolfe Research |
| 10/21/2022 | $70.00 | Buy | UBS |
| 8/22/2022 | $70.00 → $80.00 | Neutral → Buy | Citigroup |
| 2/14/2022 | $84.00 → $85.00 | Outperform | SVB Leerink |
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
Bruker Corporation (NASDAQ:BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Stifel 2024 Healthcare Conference in New York City Monday, November 18, 2024, at 8:35 a.m. Eastern Time Wolfe Research 2024 Healthcare Conference in New York City Tuesday, November 19, 2024, at 4:10 p.m. Eastern Time Nasdaq 51st Investor Conference in London, UK Tuesday, December 10, 2024, at 6:30 a.m. Eastern Time Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays of the presentations will be posted in
This strategic partnership leverages the complementary strengths of Dragonfly Energy and Bruker, bringing Dragonfly Energy's thorough expertise in liquid and solid-state battery technology together with Bruker's comprehensive suite of analytical solutions for battery research, development and manufacturingThe collaboration provides a path toward improving Dragonfly Energy's current and next-generation battery technologies and analytical testing methods using Bruker equipment and analytical expert knowledgeBruker's involvement greatly enhances Dragonfly Energy's in-depth scientific understanding of batteries and battery materials through advanced analytical methods based on magnetic resonance
New Technology Expands Antibody Compatibility and Doubles Throughput while maintaining Tissue Integrity and Lack of Cross-Reactivity Bruker Corporation (NASDAQ:BRKR) today announced a major technological breakthrough in the CellScape™ Precise Spatial Proteomics platform for highly multiplexed immunofluorescence (IF). Launched in 2022, the CellScape platform has advanced the field of spatial proteomics with differentiated quantitative performance enabled by a unique combination of best-in-class resolution and high dynamic range (HDR) imaging. CellScape captures the entire continuum of protein expression in a biological sample—from least to most abundant—while capturing fine morphological de
Q3 2024 revenues of $864.4 million, up 16.4% year-over-year (yoy); Bruker organic revenue up 3.1% yoy, and CER revenue up 15.7% yoy; BSI segment organic revenue up 3.8% yoy Q3 2024 GAAP diluted EPS $0.27; non-GAAP diluted EPS $0.60 Updated FY2024 guidance: Revenue $3.34 to $3.37 billion, implying Bruker organic revenue growth of 3% to 4%, and CER revenue growth of approximately 13% yoy Non-GAAP EPS of $2.36 - $2.41 Bruker Corporation (NASDAQ:BRKR) today announced financial results for its third quarter and for the nine months ended September 30, 2024. Frank H. Laukien, Bruker's President and CEO, commented: "Bruker has again posted double-digit year-over-year CER revenue growt
Bruker Corporation (NASDAQ:BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q3 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-
Robust, Unbiased and Affordable 4D-Proteomics™ for Highest-Specificity Protein IDs & Quant Enables High-Fidelity Large-Scale Plasma Proteomics Typical Sequence Coverage >10 Peptides/protein and >100k Peptides per Cell-Line Proteome Ushers in HiFi Proteomics with High Isoform Specificity Novel diagonal-PASEF® methods for immunopeptidomics and PTM characterization Achieving one-hundred-dollar high-fidelity plasma proteomics with PreOmics ENRICH™ and robust timsTOF HT acquisition for deep, unbiased plasma proteomics at scale with 99% specificity (1% FDR) In parallel, Biognosys introduces discovery services with P2 enrichment and Spectronaut® 19 for ultra-deep plasma proteomics with 7k
Bruker Corporation (NASDAQ:BRKR) today announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the "928 Patent"), which has been asserted by 10x Genomics against NanoString's CosMx® Spatial Molecular Imager (SMI) products in Europe. Today's ruling follows the May 2024 decision of the German Federal Patent Court, which declared the 928 Patent invalid and revoked the patent in Germany. An appeal is pending in that case. Today's decision of the UPC expands on that German invalidity ruling to further invalidate the 928 Patent in France and The Netherlands. The ruling of the UPC is subject to appeal. "We a
Biognosys' proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensingBy offering the combination of NULISA™ affinity-based assays and TrueDiscovery® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive solutions for plasma proteomics Spectronaut® workflows for high-performance computing environments, post-translational modifications, and protein-turnover profiling elevate the scale and scope of DIA proteomics SpectroDive™ 12 delivers breakthrough performance for targeted proteomics workflows, with novel features f
Bruker Spatial Biology Offers the Widest Range of Industry-leading Multiomic Spatial Biology Platforms to Scientists Globally Bruker Corporation (NASDAQ:BRKR) today announced the formation of a new division, Bruker Spatial Biology, offering the most diverse and comprehensive solutions for spatial biology. Bruker Spatial Biology brings together in operational coordination three entities: the two businesses of NanoString Technologies and Canopy Biosciences, along with its subsidiary Bruker Spatial Genomics, Inc. (formerly known as Acuity Spatial Genomics, Inc.). Bruker Spatial Biology will focus on elevating the industry's most promising technologies for the advancement of biomedical resear
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
Bruker Corporation (NASDAQ:BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q3 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-
Combining Dynamic Biosensors' Innovative Technologies with Bruker's High-Performance SPR Portfolio to Establish a Leading Biosensors Business Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker's biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on September 16, 2024 to stockholders of record as of September 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, an
Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue growth of 5% to 7% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its second quarter and for the six months ended June 30, 2024. Frank H. Laukien, Bruker's President and CEO, commented: "Our teams delivered excellent revenue growth in the second quarter and a solid first half of 2024, despite soft general market condi
Bruker Corporation (NASDAQ:BRKR) today announced it will report second quarter 2024 financial results before market opening on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q2 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on June 17, 2024 to stockholders of record as of June 3, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microsco
Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenue up 5.5% yoy Q1 2024 GAAP EPS of $0.35; non-GAAP EPS of $0.53 Updated FY 2024 guidance: Revenue $3.29 to $3.35 billion, up $60 million from prior guidance, implying reported growth of 11% to 13% yoy. Organic revenue growth maintained at 5% to 7% yoy CER revenue growth of 12% to 14% yoy, including closed Chemspeed and ELITech acquisitions, up from prior guidance of 8% to 10% yoy Non-GAAP EPS of $2.79 to $2.84, up $0.08 from prior guidance, including ELITech EPS accretion, but excluding still pending EPS-dilutive NanoString acquisition
Bruker Corporation (NASDAQ:BRKR) today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q1 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-41
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on March 15, 2024 to stockholders of record as of March 1, 2024. About Bruker Corporation Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling i
Barclays initiated coverage of Bruker with a rating of Overweight and set a new price target of $75.00
Wolfe Research downgraded Bruker from Outperform to Peer Perform
Wells Fargo initiated coverage of Bruker with a rating of Overweight and set a new price target of $78.00
Jefferies resumed coverage of Bruker with a rating of Buy and set a new price target of $85.00
JP Morgan upgraded Bruker from Neutral to Overweight and set a new price target of $90.00 from $60.00 previously
Wells Fargo initiated coverage of Bruker with a rating of Equal Weight and set a new price target of $72.00
Wolfe Research initiated coverage of Bruker with a rating of Outperform and set a new price target of $80.00
UBS initiated coverage of Bruker with a rating of Buy and set a new price target of $70.00
Citigroup upgraded Bruker from Neutral to Buy and set a new price target of $80.00 from $70.00 previously
SVB Leerink reiterated coverage of Bruker with a rating of Outperform and set a new price target of $85.00 from $84.00 previously
8-K - BRUKER CORP (0001109354) (Filer)
10-Q - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K/A - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
424B5 - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
S-3ASR - BRUKER CORP (0001109354) (Filer)
ARS - BRUKER CORP (0001109354) (Filer)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic
ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral disease ELITechGroup has its R&D, manufacturing and commercial focus on Europe and the Americas Bruker to acquire ELITechGroup revenues of ~Euro 150 million p.a. with >80% consumables revenue Bruker Corporation (NASDAQ:BRKR) announced today that
Chemspeed Accelerates Bruker's Laboratory Automation and Digitalization Drive Bruker Corporation (NASDAQ:BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125759758/en/Chemspeed's modular, compact FLEX automation workstations enhance chemical and materials science R&D and lab
Bruker (NASDAQ:BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker's biopharma PAT portfolio with its well-established products. Financial details were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240104658012/en/Tornado's proprietary product, the Process Guardian™, which offers superior performance for RAMAN biopharma process applications (Photo: Busines
High-end STEM Technology Expands Bruker's Portfolio for Materials Science Research Bruker today announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes (STEM). Nion was the first company to introduce aberration correction for STEM instruments with ultra-high stability for highest resolution images, and Nion is the world leader in ultra-high energy and spatial resolution electron energy-loss spectroscopy (EELS). This acquisition enhances Bruker's product offerings and technology portfolio in materials science research and provides the technology base for applications in electron diffraction
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005639/en/Dr. Philip Ma is Chief Executive Officer, President, and Founder of PrognomiQ (Photo: Business Wire) Dr. Ma is Chief Executive Officer, founder, and a director of PrognomiQ, a privately held healthcare company that is developing next-generation, transformative multiomics products to enable early cancer detection and cancer treatment selection and monitoring assays. Before PrognomiQ, Dr. Ma was Chief Business
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Buy and lowers the price target from $95 to $80.
Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:BRKR) with a Sell and lowers the price target from $72 to $60.
Based on cellular biophysical markers attained using Bruker's advanced atomic force microscopy, Cellens is developing its platform for detecting bladder cancer using voided urine samples from cancer patients. The technology has shown outstanding sensitivity and specificity in pilot clinical studies.
At the 72nd ASMS meeting, Bruker Corporation (NASDAQ:BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the neofleX Imaging Profiler for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new SCiLS Scope software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top. At the 72nd ASMS meeting, Bruker Corporation (NASDAQ:BRKR) launches the new top-of-the-line timsTOF Ultra 2 system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility. Together with new Spectronaut 19software and the novel
Bruker Corp (NASDAQ:BRKR) shares are trading lower by 6.6% to $67.80 during Thursday’s session after the company announced a public offering of 6 million shares of its common stock. The offering comes with an option for underwriters to purchase an additional 900,000 shares within 30 days. The offering is set to close around May 31, pending customary conditions. The proceeds will be used to reduce debt from recent strategic acquisitions, including repaying part of its revolving credit agreement. BofA Securities and J.P. Morgan are managing the offering, and the shares will be available on the Nasdaq Global Select Market and other venues at prevailing or negotiated prices. See Also:
Bruker intends to use the net proceeds from the offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borrowings under the amended and restated revolving credit agreement dated as of January 18, 2024.
Bruker Corporation ("Bruker" or the "Company") (NASDAQ:BRKR) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Bruker intends to use the net proceeds from this offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borro